Latest: FDA Approves New Biosimilar for Oncology Treatment

Analyzing Zorevunersen in Phase 3 Registrational Study for Dravet Syndrome: The EMPEROR Trial

by Neurology Live

14 September, 2025

0 Mins

Spanning across the United Kingdom, the United States, European Union, and Japan, the global phase 3 EMPEROR study of zorevunersen is expected to have data readout by the end of 2027.

Tags:

Author

Neurology Live

Renal Denervation Shows Durable Blood Pressure Benefits in Key Trials: Deepak L. Bhatt, MD, MPH, MBA

Outdoor Play to Combat Rising Childhood Anxiety—Here's How Schools Are Responding

📢

300x250 Banner

Analyzing Zorevunersen in Phase 3 Registrational Study for Dravet Syndrome: The EMPEROR Trial

Tags:

Neurology Live

Renal Denervation Shows Durable Blood Pressure Benefits in Key Trials: Deepak L. Bhatt, MD, MPH, MBA

Outdoor Play to Combat Rising Childhood Anxiety—Here's How Schools Are Responding

Recent Content

COPD Biologics: Early Treatment Insights

Antihypertensive Medication Guidelines

Juvenile Arthritis Care Transition